ArticleBMC cancer2015

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.

Iben Kümler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.